Camaisa Allan 4
4 · Calidi Biotherapeutics, Inc. · Filed Jun 20, 2024
Insider Transaction Report
Form 4
Camaisa Allan
DirectorCEO, President and Chairman10% Owner
Transactions
- Award
Stock Options (right to buy)
2024-06-17+40,000→ 40,000 totalExercise: $0.21Exp: 2029-06-17→ Common stock
Footnotes (1)
- [F1]Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on June 17, 2024 (the "Grant Date"), the Reporting Person was granted 40,000 incentive stock options at an exercise price of $0.215, which is equal to 110% of the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/48th installments on the last day of each monthly period of the Reporting Person's continued service to the Issuer, commencing on 1/1/2024. The options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.